Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0030602 (Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs